Surgical Science Sweden AB (publ) (SUS.ST) : juste valeur

Thèse ACCE

Surgical Science makes the LapNav and LapNav Mini laparoscopic simulators, a training platform for surgeons and surgical teams that the company sells to hospitals and medical schools, with its LapNav Surgery and virtual reality training content as recurring add-ons. The model rests on a 66.5% gross margin, which points to software-like economics on hardware and content sold into a training market where surgeons need repeat practice to keep skills current. The near-term driver is revenue growth of 21.7%, which the company is converting into operating profit at a 16.4% margin, so the earnings base is starting to catch up with the top line. The stock trades at 31.6 times trailing earnings but 11.8 times forward earnings, a gap that implies a sharp expected step-up in profitability that needs verifying before anyone relies on it. A ROE of 2.1% says the equity base is still thin relative to the business, and the lack of index membership at a 2.9 billion SEK market cap means liquidity and coverage are likely limited, so this warrants a deeper look at the forecast assumptions and cash generation rather than a conclusion on valuation alone.